ArticleFrontiers in oncology2026
Prognostic model for three-year postoperative local recurrence in cutaneous squamous cell carcinoma: a Chinese multicenter cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) carries a risk of postoperative local recurrence, with nearly 90% of events occurring within 3 years; however, prognostic tools tailored to Asian populations remain limited. This study aimed to identify independent risk factors for postoperative local recurrence and develop a nomogram to predict individualized 1-, 2-, and 3-year recurrence probabilities in patients with cSCC. Methods: Clinicopathological data from 603 patients with cSCC who underwent surgical treatment alone at four Chinese centers were retrospectively analyzed. Patients were randomly divided into a training cohort and a validation cohort at a ratio of 7:3. Univariable and multivariable Cox proportional hazards regression analyses were performed in the training cohort to identify independent predictors of postoperative local recurrence. A nomogram was then constructed based on these independent risk factors. The prognostic performance of the model was evaluated using time-dependent receiver operating characteristic curves, calibration curves, and decision curve analysis. Finally, the total nomogram score was calculated for each patient, and all patients were categorized into low-, intermediate-, and high-risk groups based on the optimal cutoff values. Kaplan-Meier analysis was then performed to compare recurrence-free survival among the different risk groups. Results: A total of 603 patients were included, with 422 in the training cohort and 181 in the validation cohort. During follow-up, 77 recurrence events were observed. Multivariable Cox regression identified age, tumor size, tumor thickness, histologic differentiation, regional stage, and AJCC stage as independent predictors of recurrence. These predictors were incorporated into a nomogram for individualized recurrence risk estimation. The model demonstrated good discrimination, with area under the curve values ranging from 0.759 to 0.869, along with strong calibration and favorable clinical utility in decision curve analysis. Based on the total nomogram score, patients were stratified into low-risk (<99.0), intermediate-risk (99.0-143.9), and high-risk (≥144.0) groups, with significant differences in recurrence-free survival among the three groups (log-rank p < 0.0001). Conclusions: This nomogram provides a practical tool for individualized prognostic assessment and may support individualized clinical decision-making for 1-, 2-, and 3-year outcomes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.